Clinical Trials Browser

Recruiting × darolutamide × 90 days × Clear all

NCT05348876 2026-03-19

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4 Recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT06282588 2026-03-19

THUNDER

Phase 2/3 Recruiting

493 enrolled

Genitourinary

Prostatic Neoplasms

NCT07103018 2026-03-16

STRIKE-001

Phase 1 Recruiting

144 enrolled

Genitourinary

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Phase 2 Recruiting

75 enrolled

Genitourinary

Prostatic Neoplasms

NCT06334120 2026-03-12

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Recruiting

600 enrolled

Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT07190300 2026-03-02

TulmiSTAR-02

Phase 1/2 Recruiting

155 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT05938270 2026-02-24

ASCERTAIN

Phase 1 Recruiting

120 enrolled

Genitourinary

Prostatic Neoplasms

NCT05997615 2026-02-24

AMX-500

Phase 1 Recruiting

390 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06724159 2026-02-17

SOGUG-PRINCIS

Recruiting

500 enrolled

Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Phase 1 Recruiting

277 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07406282 2026-02-12

Double-DARE

Recruiting

1,400 enrolled

Genitourinary

Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Phase 1 Recruiting

30 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Recruiting

60 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06120491 2026-01-21

EvoPAR-PR01

Phase 3 Recruiting

1,800 enrolled

Genitourinary

Prostatic Neoplasms

NCT05519449 2026-01-20

ENGAGER-PSMA-01

Phase 1 Recruiting

272 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05050084 2026-01-14

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Phase 3 Recruiting

2,050 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT06592924 2026-01-14

TRIPLE-SWITCH

Phase 3 Recruiting

830 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

Phase 2 Recruiting

532 enrolled

Genitourinary

Prostatic Neoplasms